Delivery Order SPE2DB25D9317-SPE2DB25FVGFV
Award Date
4/18/25
Potential Completion Date
5/9/25
Potential Value
$10K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of Nexplanon 68 mg implants. The contract, valued at $6,943.10, has an ultimate completion date of May 12, 2025. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the agency to issue delivery orders...
This federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of NEXPLANON 68 MG IMPLANTS. The firm fixed-price contract has a ceiling value of $8,331.72 and a period of performance through July 7, 2025. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a comprehensive...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is for the delivery of 68 mg Nexplanon implants. The $14,293.80 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division, which distributes pharmaceuticals and medical supplies to Department of Defense (DoD) healthcare facilities. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with...
This contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of Nexplanon 68 mg implants to the Defense Logistics Agency (DLA) Medical Supply Chain. The firm fixed-price delivery order, valued at $2,858.76, has a period of performance through July 17, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. This single-award vehicle, under...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order valued at $14,293.80 for the supply of Nexplanon 68 MG implants. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of October 9, 2024. The contract is a firm fixed-price delivery order with no set-aside designation, leveraging DMS Pharmaceutical Group's status as a woman-owned small business. This award is part of a...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the delivery of Nexplanon 68 mg implants. The contract has a ceiling value of $8,576.28 and a period of performance through December 2, 2024. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued up to $499,999,999 and valid through November...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order with a ceiling value of $4,288.14. The contract is for the supply of Nexplanon 68 mg implants, a contraceptive product, to the Defense Logistics Agency (DLA) under the Medical Supply Chain division. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of Nexplanon 68 mg implants, with a ceiling value of $7,146.90 and a period of performance through February 20, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is for the supply of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA). The $7,146.90 firm fixed-price delivery order has an ultimate completion date of September 17, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a...
This is a $4,165.86 firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA). The order is for NEXPLANON 68 MG IMPLANTS, with a performance period through July 24, 2025. DMS Pharmaceutical Group has a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables DLA to issue delivery orders for a...